Form 4 for PYXS Pyxis Oncology, Inc.
Accepted 2022-04-04 00:00:00 ET · period of report 2022-03-31 · accession 0001140361-22-012924 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-04-04 | 2022-03-31 | PYXS | Sullivan Lara | CEO, Dir | A - Grant | $0.00 | +742.6K | 1.04M | +249% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-31 | A | A | 742,574 | $0.00 | 1,041,363 | D | — | — | (F1) Represents restricted stock units that vest over a four-year period, with 25% vesting on the first anniversary of the grant date, and the remaining 75% vesting in 12 substantially-equal quarterly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. |